Department of Medicine, Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon 97239, USA.
Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):321-9. doi: 10.1097/MED.0b013e32836318a1.
This review focuses on combination drug treatment for acromegaly patients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience.
A review of published clinical studies demonstrates that combination therapy; somatostatin receptor ligands and dopamine agonists, somatostatin receptor ligands and pegvisomant, or cabergoline and pegvisomant could provide significant additive biochemical control of acromegaly in patients inadequately controlled with conventional somatostatin receptor ligand therapy.
Advances in combination medical therapy have opened up new perspectives for acromegaly patients who are poorly, or nonresponsive to, presently available single drug therapies.
本篇综述聚焦于肢端肥大症患者的联合药物治疗，包括新的概念和实验性治疗，重点介绍作者的个人经验。
对已发表的临床研究的回顾表明，联合治疗——生长抑素受体配体和多巴胺激动剂、生长抑素受体配体和培维索孟，或卡麦角林和培维索孟，可在常规生长抑素受体配体治疗效果不佳的患者中提供显著的生化控制叠加作用。
联合药物治疗的进展为目前对单一药物治疗反应不佳或无反应的肢端肥大症患者开辟了新的前景。
